



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Image 1652 4

In re Application of: YAN, Chunhua et al.

Art Unit: 1652

Serial No.: 10/067,977

Examiner: RAO, M.

Filed: February 8, 2002

Atty. Docket: CL001313

For: ISOLATED HUMAN KINASE PROTEINS, NUCLEIC
ACID MOLECULES ENCODING HUMAN KINASE
PROTEINS, AND USES THEREOF

**Statement Regarding Duty to Disclose Information Material To Patentability Under
37 CFR 1.56 (a) and (b)**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants hereby notify the US Patent and Trademark Office of the documents listed on the attached PTO Form SB/08A, which may be deemed relevant to the patentability of the claims of the above application. One copy of each of the listed documents is submitted herewith. The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application.

The undersigned states that each item listed on the attached PTO Form SB/08A was first cited in a communication from a Foreign Patent Office in the above application's foreign counterpart or not known to the Undersigned for more than three months prior to the filing of this Information Disclosure Statement.

02/13/2004 HALI11 00000039 500970 10067977
01 FC:1806 180.00 DA

Please charge the fee set forth in §1.17(p) to deposit account number 50-0970.

Furthermore, the Office is authorized to charge any other necessary fees related to the processing of this application to Deposit Account No. 50-0970.

Respectfully submitted,

CELERA GENOMICS

Date: February 11, 2004

By: 

Justin D. Karjala, Reg No. 43,704

Celera Genomics Corporation
45 West Gude Drive, C2-4#21
Rockville, MD 20850
Tel: 240-453-3812
Fax: 240-453-3084

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/067,977
Filing Date	February 8, 2002
First Named Inventor	Chunhua YAN et al.
Art Unit	1652
Examiner Name	Manjunath N. Rao
Attorney Docket Number	CL001313

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials ²	Cite No. ¹	Foreign Patent Document ³		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³	Number ⁴ - Kind Code ⁵ (if known)				
		WO 98 11234		3/19/1998	Incyte Pharmaceuticals Inc.		
		EP 0 887 081 A2		12/30/1998	SmithKline Beecham Corp.		
		EP 0 861 896 A2		09/02/1998	Dade Behring Marburg GmbH		

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST: 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2

of 2

Complete if Known

Application Number	10/067,977
Filing Date	February 8, 2002
First Named Inventor	Chunhua YAN et al.
Group Art Unit	1652
Examiner Name	Manjunath N. Rao
Attorney Docket Number	CL001313

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Database GenBank, US National Library of Medicine, (Bethesda, MD, USA) No. AAW90139, KUMAN JM, March 1999.	
		Database GenBank, US National Library of Medicine, (Bethesda, MD, USA) No. AAW77217, LANG et al., November 1998.	
		Database GenBank, US National Library of Medicine, (Bethesda, MD, USA) No. AAB2115, YU et al., January 2001.	
		Database GenBank, US National Library of Medicine, (Bethesda, MD, USA) No. AAB65613, PLOWMAN et al., March 2001.	
		Database GenBank, US National Library of Medicine, (Bethesda, MD, USA) No. AAW52025, AU-YOUNG et al., March 2001.	
		EP 0 887081 A2 (SMITHKLINE BEECHAM CORP) 30 December 1998 (30.12.1998) see entire document.	
		EP 0 861896-A2 (DADE BEHRING MARBUG GMBH) 02 September 1998 (02.09.1998) see entire document.	
		WO 98/11234-A2 (INCYTE PHARM INC.) 19 March 1998 (19.03.1998) see entire document.	
		International Search Report dated January 15, 2004.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.